Diabetes confers in vitro calcific potential on serum which associates with in-vivo vascular calcification.

dc.cclicenceCC-BY-NCen
dc.contributor.authorPatidar, A.en
dc.contributor.authorSingh, D.en
dc.contributor.authorThakur, S.en
dc.contributor.authorWinocour, P.en
dc.contributor.authorFarrington, K.en
dc.contributor.authorBaydoun, Anwaren
dc.date.accessioned2018-10-31T15:02:46Z
dc.date.available2018-10-31T15:02:46Z
dc.date.issued2017-05-09
dc.descriptionopen access articleen
dc.description.abstractAlthough vascular calcification (VC) is prevalent in Type 2 diabetes mellitus (T2DM), underlying mechanisms remain unclear. Neither is it known whether T2DM confers calcific potential (CP) on serum, enabling it to induce VC outside the disease milieu. We, therefore, investigated the CP of serum from controls and subjects with T2DM with and without in vivo VC. Samples from 20 healthy controls and 44 age- and sex-matched patients with T2DM with modification of diet in renal disease estimated glomerular filtration rate (MDRD-4 eGFR) > 60 ml·min-1 were analysed for CP using rat aortic smooth muscle cells in vitro CT scans of femoral arteries identified individuals with in vivo calcification. Serum from subjects with T2DM revealed significantly greater CP than controls. This was further enhanced in the presence of in vivo VC. Addition of β-glycerophosphate (β-GP) plus CaCl2 increased the CP of T2DM serum but not of controls. Along with age, CP was an independent predictor of the presence of VC. In receiver operator curve (ROC) analysis, CP was a significant predictor of femoral arterial VC (C-statistic 0.70: P=0.009). The distribution of CP was bimodal around a cutoff of 100 nmoles of Ca2+ protein mg-1, with a higher proportion of Type 2 diabetes subjects with in vivo calcification (T2DM+) sera above the cutoff value. This group also showed elevated levels of osteoprotegerin (OPG) and matrix Gla protein (MGP). Diabetes confers CP on the serum which is enhanced by the presence of in vivo VC. The CP acquired may be dependent on levels of OPG and MGP. These findings may be clinically relevant for early identification of individuals at risk of VC and for informing therapeutic strategies.en
dc.funderN/Aen
dc.identifier.citationPatidar, A. et al. (2017) Diabetes confers in vitro calcific potential on serum which associates with in-vivo vascular calcification. Clinical Science, 131 (10), pp. 991-1000en
dc.identifier.doihttps://doi.org/10.1042/CS20160882
dc.identifier.urihttp://hdl.handle.net/2086/16960
dc.language.isoenen
dc.peerreviewedYesen
dc.projectidN/Aen
dc.publisherPortland Pressen
dc.researchinstituteLeicester Institute for Pharmaceutical Innovation - From Molecules to Practice (LIPI)en
dc.titleDiabetes confers in vitro calcific potential on serum which associates with in-vivo vascular calcification.en
dc.typeArticleen

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cs-131-cs20160882.pdf
Size:
437.17 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.2 KB
Format:
Item-specific license agreed upon to submission
Description: